Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment · Journal article
European Journal of Nuclear Medicine and Molecular Imaging · September 8, 2026
Reinforces what was already believed, rather than introducing something new.
This is an external validation of the Bellmunt Risk Score (BRS) in an independent cohort of 243 mCRPC patients treated with [177Lu]Lu-PSMA-617, confirming that a simple three-component score—ECOG performance status >0, hemoglobin <10 g/dL, and liver metastases—reliably stratifies patients by survival risk. The score achieved a time-dependent AUC of 71.3% for 1-year OS prediction and remained independently predictive in multivariable analysis, supporting its use as a pragmatic prognostic tool in this population.
Retrospective external validation cohort study. 243 mCRPC patients treated with [177Lu]Lu-PSMA-617 at an independent tertiary center; detailed eligibility criteria and baseline characteristics not specified in abstract.. Intervention: [177Lu]Lu-PSMA-617 therapy. Compared with: Bellmunt Risk Score (BRS) strata (0, 1, 2, 3) compared within cohort for survival prediction. n = 243. Single independent tertiary center; specific location not stated..
Median OS by BRS stratum: BRS 0 = 24.0 months, BRS 1 = 15.8 months, BRS 2 = 11.2 months, BRS 3 = 8.7 months (p < 0.001) BRS 2 and BRS 3 were independent predictors of shortened OS in multivariable Cox regression adjusted for prior treatment lines (BRS 2: HR 3.04, p < 0.001; BRS 3: HR 4.76, p = 0.002) Time-dependent AUC for 1-year OS prediction: 71.3%
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians can apply this simple, easily calculable three-component score at baseline to risk-stratify mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy and inform prognostic counselling. The robust external validation supports routine adoption for prognostication, though the score does not guide treatment selection and remains descriptive rather than prescriptive.
External validation of an established prognostic score in an independent cohort, demonstrating reproducibility of risk stratification and survival prediction with robust performance metrics, but not introducing new clinical intervention or changing treatment selection.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians can apply this simple, easily calculable three-component score at baseline to risk-stratify mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy and inform prognostic counselling. The robust external validation supports routine adoption for prognostication, though the score does not guide treatment selection and remains descriptive rather than prescriptive.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Purpose [ 177 Lu]Lu-PSMA-617 is a standard-of-care therapy for metastatic castration-resistant prostate cancer (mCRPC). Given the heterogeneous clinical responses, accessible prognostic tools are needed. We recently demonstrated that the Bellmunt Risk Score (BRS)—comprising ECOG performance status >0, hemoglobin <10 g/dL, and the presence of liver metastases—predicts overall survival (OS) in a primary mCRPC cohort. This study aims to externally validate the BRS in an independent cohort. Methods We retrospectively evaluated 243 mCRPC patients treated with [ 177 Lu]Lu-PSMA-617 at an independent tertiary center. The BRS was calculated at baseline (range 0-3). Endpoints included OS analyzed via Kaplan-Meier estimators, multivariable Cox regression, Harrell’s C-index, and time-dependent area under the curve (tAUC). Results The cohort was distributed into BRS 0 (17.6%), BRS 1 (52.7%), BRS 2 (26.1%), and BRS 3 (2.9%). Kaplan-Meier analysis revealed significant risk stratification, with an estimated median OS of 24.0, 15.8, 11.2, and 8.7 months for BRS 0, 1, 2, and 3, respectively ( p < 0.001). In univariable analysis, BRS significantly predicted survival. In multivariable Cox regression adjusted for the number of prior treatment lines, BRS 2 (HR 3.04, p < 0.001) and BRS 3 (HR 4.76, p = 0.002) remained independent predictors of shortened OS. The BRS demonstrated robust predictive accuracy, achieving a tAUC of 71.3% for 1-year OS. Conclusion The BRS is a pragmatic, robust, and easily calculable prognostic tool for mCRPC patients undergoing [ 177 Lu]Lu-PSMA-617 therapy, successfully validated in an independent external cohort.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.